Ad
Tuesday, 28 November 2017
Merck KGaA, Pfizer's avelumab misses goal in gastric cancer trial
FRANKFURT (Reuters) - Germany's Merck KGaA said on Tuesday that its cancer immunotherapy avelumab, jointly developed with Pfizer, failed to improve overall survival compared with standard chemotherapy in a late-stage study on gastric cancer patients.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment